Status:

COMPLETED

Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis

Lead Sponsor:

Tehran University of Medical Sciences

Conditions:

Autoimmune Hepatitis

Eligibility:

All Genders

16-65 years

Phase:

PHASE3

Brief Summary

Untreated Autoimmune hepatitis (AIH) is a progressive disease. Mainstay of treatment are corticosteroids (CS). In addition to being ineffective a substantial minority of cases, corticosteroid side-eff...

Eligibility Criteria

Inclusion

  • 16-65 years old individuals with probable of definite AIH according to the revised AIH criteria.
  • Willing and able to participate in the study

Exclusion

  • Non-consenting patients
  • decompensated cirrhosis, i.e. clinical ascites, hepatic encephalopathy, history of variceal bleeding
  • Presence of serious concomitant cardiovascular, pulmonary or renal condition
  • Presence of active malignant disorder

Key Trial Info

Start Date :

December 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2018

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT01170351

Start Date

December 1 2005

End Date

December 1 2018

Last Update

July 19 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Digestive Disease Research Center, Shariati Hospital

Tehran, Iran, 14117

Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis | DecenTrialz